Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation
Giuseppe Boriani, MDa,
Mauro Biffi, MDa,
Alessandro Capucci, MDa,
Gabriele Bronzetti, MDa,
Gregory M. Ayers, MD, PhD*,
Romano Zannoli, BSa,
Angelo Branzi, MDa and
Bruno Magnani, MDa
a Institute of Cardiology, University of Bologna, Bologna, Italy
* In Control Inc., Redmond, Washington, USA
View larger version (195K):
[in a new window]
|
Figure 1 Catheter placement at fluoroscopy (anteroposterior view) with a quadripolar catheter at right ventricular apex, a decapolar catheter in coronary sinus, and a decapolar catheter in right lateral atrial wall.
|
|
View larger version (11K):
[in a new window]
|
Figure 2 Study design: Flow chart of the study protocol in patients with paroxysmal atrial fibrillation (PAF) or chronic persistent atrial fibrillation (CAF) not submitted to atrial cardioversion retesting in a drug-free condition. AF = atrial fibrillation.
|
|
View larger version (14K):
[in a new window]
|
Figure 3 Study design: Flow chart of the study protocol in patients with paroxysmal atrial fibrillation (PAF) or chronic persistent atrial fibrillation (CAF) submitted to atrial cardioversion retesting in a drug-free condition. AF = atrial fibrillation.
|
|
View larger version (21K):
[in a new window]
|
Figure 4 Leading-edge voltage (top) and delivered energy (bottom) for effective shocks in patients with paroxysmal or persistent atrial fibrillation (AF) at baseline and after flecainide administration.
|
|
View larger version (26K):
[in a new window]
|
Figure 5 Surface ECG recordings (leads aVR and D1) and intracavitary bipolar recordings (HRA = high right atrium; CS = coronary sinus) in a patient at baseline (top) and after flecainide IV infusion (bottom). A lengthening of atrial fibrillation cycle is evident in either HRA or CS recordings.
|
|
|
